[go: up one dir, main page]

AR082411A1 - siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO - Google Patents

siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO

Info

Publication number
AR082411A1
AR082411A1 ARP110102737A ARP110102737A AR082411A1 AR 082411 A1 AR082411 A1 AR 082411A1 AR P110102737 A ARP110102737 A AR P110102737A AR P110102737 A ARP110102737 A AR P110102737A AR 082411 A1 AR082411 A1 AR 082411A1
Authority
AR
Argentina
Prior art keywords
vegfa
sirna
syrna
aimed
treatment methods
Prior art date
Application number
ARP110102737A
Other languages
English (en)
Inventor
Angela Reynolds
Jon E Chatterton
Xinyu Zhang
Anja Smith
Original Assignee
Dharmacon Inc
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45527345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dharmacon Inc, Alcon Res Ltd filed Critical Dharmacon Inc
Publication of AR082411A1 publication Critical patent/AR082411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)

Abstract

El factor de crecimiento endotelial vascular A (VEGFA) es una señal química producida por células que estimulan el crecimiento de nuevos vasos sanguíneos y la sobreexpresión del VEGFA puede llevar a condiciones fisiológicas no deseadas. Mediante la identificación del nuevo siRNA y modificaciones que mejoran la habilidad de silenciar dicho siRNA in vivo se han preparado composiciones y métodos terapéuticos para tratar los problemas asociados con dicha sobreexpresión.Reivindicación 1: Un método para disminuir la expresión del VEGFA in vivo, que comprende la administración de un siRNA a un sujeto, en donde el siRNA comprende una secuencia que es una secuencia seleccionada de SEQ ID Nº 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, y 88.
ARP110102737A 2010-07-28 2011-07-28 siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO AR082411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36838510P 2010-07-28 2010-07-28

Publications (1)

Publication Number Publication Date
AR082411A1 true AR082411A1 (es) 2012-12-05

Family

ID=45527345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102737A AR082411A1 (es) 2010-07-28 2011-07-28 siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO

Country Status (17)

Country Link
US (2) US8546349B2 (es)
EP (1) EP2598639A4 (es)
JP (1) JP2013539456A (es)
KR (1) KR20130095737A (es)
CN (1) CN103068981A (es)
AR (1) AR082411A1 (es)
AU (1) AU2011282902B2 (es)
BR (1) BR112013001918A2 (es)
CA (1) CA2804847A1 (es)
CL (1) CL2013000237A1 (es)
MX (1) MX2013000986A (es)
PH (1) PH12013500187A1 (es)
RU (1) RU2013102545A (es)
TW (1) TW201219041A (es)
UY (1) UY33533A (es)
WO (1) WO2012015775A2 (es)
ZA (1) ZA201300531B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505272QA (en) * 2013-01-08 2015-08-28 Benitec Biopharma Ltd Age-related macular degeneration treatment
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
TWI496595B (zh) * 2013-06-07 2015-08-21 Univ Nat Taiwan Ocean 製備魚類核醣核酸試劑之方法
EP3138293A4 (en) * 2014-04-29 2017-05-24 Microsoft Technology Licensing, LLC Encoder-side decisions for sample adaptive offset filtering
EP3294880A4 (en) * 2015-05-15 2018-12-26 Dharmacon, Inc. Synthetic single guide rna for cas9-mediated gene editing
WO2017173327A1 (en) * 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
GB201802404D0 (en) * 2018-02-14 2018-03-28 Univ Malta Methods
CA3096938A1 (en) * 2018-04-10 2019-10-17 Ottawa Hospital Research Institute Microrna-based compositions and methods used in disease treatment
US20220331433A1 (en) * 2019-09-06 2022-10-20 The Regents Of The University Of California Nucleic acid-mediated delivery of therapeutics
CA3170377A1 (en) * 2020-02-10 2021-08-19 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing vegf-a expression
WO2025067351A2 (en) * 2023-09-27 2025-04-03 Neuro3 Therapeutics, Inc. Novel sirna constructs, therapeutics, and modifications

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US6150092A (en) 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US5830879A (en) 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
AU1686997A (en) 1995-12-08 1997-06-27 Hybridon, Inc. Modified vegf antisense oligonucleotides for treatment of skin disorders
AU1279397A (en) 1995-12-08 1997-07-03 Hybridon, Inc. Modified vegf antisense oligonucleotides
AU2733697A (en) 1996-04-17 1997-11-07 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression
WO1998027425A1 (en) 1996-12-19 1998-06-25 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
JP4627369B2 (ja) 1998-06-10 2011-02-09 バイオグノスティック ゲゼルシャフト フュア バイオモレキュラー ダイアグノスティック ミット ベシュレンクテル ハフツング 免疫系を刺激する方法
AU1908000A (en) 1998-11-06 2000-05-29 Basf Aktiengesellschaft Inhibition of the formation of vascular hyperpermeability
CA2422934A1 (en) 2000-10-13 2002-04-18 Institut De Cardiologie De Montreal Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof
AU2002305236A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1390385A4 (en) 2001-05-29 2004-11-24 Sirna Therapeutics Inc MODULATION OF DISEASES AND DISEASES OF THE FEMALE REPRODUCTION SYSTEM BASED ON NUCLEIC ACID
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20100113307A1 (en) 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
JP4605799B2 (ja) * 2003-04-02 2011-01-05 ダーマコン， インコーポレイテッド Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
JP2008167739A (ja) * 2006-06-14 2008-07-24 National Institute Of Advanced Industrial & Technology Ｒｎａ干渉効果が高い修飾型二本鎖ｒｎａ
US8252755B2 (en) 2006-09-22 2012-08-28 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
WO2008045576A2 (en) * 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
US20100216865A1 (en) * 2007-09-12 2010-08-26 Elias Jack A MicroRNA COMPOSITIONS IN THE TREATMENT OF VEGF-MEDIATED DISORDERS
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
JP2011518117A (ja) * 2008-03-05 2011-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
SG171952A1 (en) * 2008-12-04 2011-07-28 Opko Ophthalmics Llc Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms

Also Published As

Publication number Publication date
US8546349B2 (en) 2013-10-01
AU2011282902A1 (en) 2013-01-31
MX2013000986A (es) 2013-07-03
CL2013000237A1 (es) 2014-03-21
JP2013539456A (ja) 2013-10-24
CA2804847A1 (en) 2012-02-02
US9150862B2 (en) 2015-10-06
UY33533A (es) 2012-02-29
ZA201300531B (en) 2014-03-26
TW201219041A (en) 2012-05-16
US20140031414A1 (en) 2014-01-30
WO2012015775A3 (en) 2012-08-09
WO2012015775A2 (en) 2012-02-02
CN103068981A (zh) 2013-04-24
EP2598639A2 (en) 2013-06-05
KR20130095737A (ko) 2013-08-28
AU2011282902B2 (en) 2015-01-29
BR112013001918A2 (pt) 2016-05-24
US20120029051A1 (en) 2012-02-02
PH12013500187A1 (en) 2013-04-08
EP2598639A4 (en) 2014-08-13
RU2013102545A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
AR082411A1 (es) siRNA DIRIGIDO AL VEGFA Y METODOS DE TRATAMIENTO IN VIVO
Gangadaran et al. Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
WO2010065671A3 (en) Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
WO2011049414A3 (ko) 지방조직 유래 성체 줄기세포 이동을 유도하는 방법
MX2010005018A (es) Tratamiento de complicaciones de nacimiento prematuro.
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
MX2010003217A (es) Celulas angiogenicas de perfundido de placenta humana.
MX374806B (es) Metodo, fabricacion y uso de productos medicos que liberan sustancia activa para mantener vasos sanguineos abiertos
WO2011002239A3 (ko) 포유류의 유핵세포에서 유래된 마이크로베시클 및 이의 용도
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
IN2014MN01981A (es)
NZ601919A (en) Cell-scaffold constructs
MX2010007887A (es) Tratamiento y prevencion de condiciones cardiacas utilizando dos o mas isoformas del factor de crecimiento de hepatocitos.
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
WO2017043953A3 (es) Proceso de obtención de un compuesto de aspersión de células endoteliales microvasculares de piel y células madre mesenquimales y su método de aplicación para la regeneración tisular
SG11201804755VA (en) Method for manufacturing tissue/organ by using blood cells
Hu et al. Autophagy protein 5 enhances the function of rat EPCs and promotes EPCs homing and thrombus recanalization via activating AKT
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2013078376A3 (en) Isoxazole treatments for diabetes
RU2013121802A (ru) Профилактический или терапевтический агент для лечения фиброза
JP2012507997A5 (es)
TW201613621A (en) Composition for promoting growth of dermal papilla cells, pharmaceutical composition, and preparation method thereof
NZ702666A (en) A method of weight reduction

Legal Events

Date Code Title Description
FB Suspension of granting procedure